This pathway plays a crucial role in the development of neuropathic pain, inflammatory mechanical pain, and cancer-related pain.44,45 Aberrant activation of the PI3K/Akt signaling is commonly observed in cancer-induced pain.46 In the BCP model, the analgesic effects were noted through the inhibition of the PI3K/Akt/WNK1 pathway.12 Furthermore, inhibiting the PI3K/Akt/mTOR pathway in the periaqueductal gray region resulted in a reduction in hyperalgesic responses in BCP rats.47 Our research revealed a consistent increase in PI3K/Akt signaling in BCP rats. The gene discussed is PIK3CA; the disease is cancer.